首页> Drug design, development and therapy> Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.

Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.

导出 LinkOut

翻译打印收藏纠错

第一作者： Hae Won,Lee

第一单位： Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.;Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea.

作者： Hae Won,Lee ^[1] ; Sook Jin,Seong ^[1] ; Woo Youl,Kang ^[1] ; Boram,Ohk ^[1] ; Mi-Ri,Gwon ^[1] ; Bo Kyung,Kim ^[1] ; Seungil,Cho ^[1] ; Kyunghee,Cho ^[2] ; Yong Kyung,Sung ^[3] ; Young-Ran,Yoon ^[1] ; Jong Gwang,Kim ^[4]

作者单位： Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.;Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea. ^[1] Analytical Research Division, Biocore Co. Ltd., Seoul, Republic of Korea. ^[2] Department of R&D, Myungmoon Pharm. Co., Ltd., Seoul, Republic of Korea. ^[3] Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Kyungpook National University Cancer Research Institute, Kyungpook National University, Daegu, Republic of Korea. ^[4]

关键词 S-1 bioequivalence gimeracil oteracil pharmacokinetics tegafur